| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 27, 2025 | Sep 29, 2025 | Kura Oncology, Inc. | CEO | Sell | 97.5 | +145,885 | 21.45% | ✗ | $327.4K |
| Sep 5, 2025 | Sep 9, 2025 | Avidity Biosciences, Inc. | Director | Sell | 5.0 | -29,500 | -30.21% | ✓ | $1.5M |
| Sep 8, 2025 | Sep 9, 2025 | Kura Oncology, Inc. | CEO | Buy | 92.5 | +50,000 | 7.93% | ✗ | $410.1K |
| Aug 12, 2025 | Aug 14, 2025 | Kura Oncology, Inc. | CEO | Buy | 92.5 | +50,000 | 8.62% | ✗ | $303.2K |
| Aug 6, 2025 | Aug 8, 2025 | Avidity Biosciences, Inc. | Director | Sell | 20.0 | -95,054 | -10.84% | ✓ | $4.3M |
| Jun 13, 2025 | Jun 17, 2025 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 23.8 | -10,800 | -19.67% | ✓ | $36.7K |
| Jun 13, 2024 | Jun 17, 2024 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 10.0 | -27,000 | -96.77% | ✓ | $89.9K |
| Jan 24, 2024 | Jan 26, 2024 | Kura Oncology, Inc. | CEO | Sell | 20.0 | -91,052 | -13.56% | ✓ | $1.8M |
| Jun 13, 2023 | Jun 15, 2023 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 53.8 | - | 0.00% | ✓ | $93.3K |
| Jun 16, 2022 | Jun 21, 2022 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 10.0 | -27,858 | -49.96% | ✓ | $72K |
| Jun 10, 2021 | Jun 11, 2021 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 20.0 | -25,748 | -96.62% | ✗ | $292.4K |
| Oct 6, 2020 | Oct 8, 2020 | Kura Oncology, Inc. | CEO | Sell | 18.8 | -261,692 | -12.39% | ✓ | $8.7M |
| Sep 11, 2020 | Sep 15, 2020 | Kura Oncology, Inc. | CEO | Sell | 27.5 | -116,901 | -5.45% | ✓ | $3.4M |
| Sep 8, 2020 | Sep 10, 2020 | Kura Oncology, Inc. | CEO | Sell | 32.5 | -88,055 | -3.97% | ✓ | $2.4M |
| Aug 24, 2020 | Aug 26, 2020 | Kura Oncology, Inc. | CEO | Sell | 42.5 | -29,621 | -1.32% | ✓ | $660.6K |
| Aug 17, 2020 | Aug 19, 2020 | Kura Oncology, Inc. | CEO | Sell | 32.5 | -75,335 | -3.22% | ✓ | $1.7M |
| Jun 11, 2020 | Jun 15, 2020 | PUMA BIOTECHNOLOGY, INC. | Director | Sell | 20.0 | -25,245 | -48.65% | ✗ | $251.7K |